Atopic dermatitis

• View the full release here: https://www.businesswire.com/news/home/20240425445928/en/
  Aldeyra will present new preclinical data from investigational RASP modulators in animal models for obesity, atopic dermatitis, inflammatory pain, and alcoholic hepatitis.
• In the diet-induced model of obesity, ADX-629 decreased weight and fat mass alone and in combination with a GLP-1 agonist.
• In the carrageenan model of inflammatory pain, ADX-246 increased tolerance to mechanical and thermal pain, and decreased joint swelling.
• Consistent with previously released data from ADX-629 in a model of alcoholic hepatitis, ADX-246 reduced levels of fibrosis and fat in liver.

• Year-on-year net sales growth on a constant currency basis for the period was 12.4%, primarily driven by volume.
• Injectable Aesthetics net sales for the first quarter of 2024 were 511 million USD, with year-on-year growth of 19.3% on a constant currency basis.
• Dermatological Skincare net sales for the first quarter of 2024 were 351 million USD, with year-on-year growth of 8.4% on a constant currency basis.
• Therapeutic Dermatology net sales for the first quarter of 2024 were 209 million USD, with year-on-year growth of 4.1% on a constant currency basis.

• Also known as atopic dermatitis, this chronic skin disease affects about 1 in 5 children in the industrialized world.
• Some studies have found rates of eczema in developing nations to be over thirtyfold lower compared with industrialized nations.
• Scientists know that factors such as diets rich in processed foods as well as exposure to specific detergents and chemicals increase the risk of developing eczema.
• Living near factories, major roadways or wildfires increase the risk of developing eczema.

There’s something in the air

• Then we looked at databases from the U.S. Environmental Protection Agency to see which chemicals were most common in those areas.
• Diisocyanates were first manufactured in the U.S. around 1970 for the production of spandex, nonlatex foam, paint and polyurethane.
• The manufacture of xylene also increased around that time, alongside an increase in the production of polyester and other materials.

• After 1975, when all new cars became outfitted with a new technology that converted exhaust gas to less toxic chemicals, isocyanate and xylene both became components of automobile exhaust.
• How directly exposing mice to these toxins compares to the typical levels of exposure in people is still unclear.

Skin microbiome and pollution

• Every person is coated with millions of microorganisms that live on the skin, collectively referred to as the skin microbiome.
• You’ve probably seen moisturizers and other skin products containing ceramides, a group of lipids that play an important role in protecting the skin.

• To see which toxins could prevent production of the beneficial lipids that prevent eczema, my team and I used skin bacteria as canaries in the coal mine.
• Lysine helps protect the bacteria from the harms of the toxins but doesn’t provide the health benefits of ceramides.
• Bacteria that help keep skin healthy could live on any fabric, but, just as with air pollution, the amount of beneficial lipids they made dropped to less than half the levels made when grown on fabrics like cotton.

Addressing pollution’s effects on skin

• Detectors capable of sensing low levels of isocyanate or xylene could help track pollutants and predict eczema flare-ups across a community.
• Better detectors can also help researchers identify air filtration systems that can scrub these chemicals from the environment.
• In the meantime, improving your microbial balance may require avoiding products that limit the growth of healthy skin bacteria.
• I believe that it may one day allow us to get back to a time when these diseases were uncommon.

Ian Myles receives funding from the Department of Intramural Research at the National Institute of Allergy and Infectious Diseases. He is the author of, and receives royalties for, the book GATTACA Has Fallen: How population genetics failed the populace. Although he is the co-discoverer of Roseomonas mucosa RSM2015 for eczema, he has donated the patent to the public and has no current conflict of interest for its sales.

• Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development.
• At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.
• Prior to Krystal, Dr. Chen was at Genentech/Roche where he held clinical leadership positions across both early and late-stage development.
• To support the ongoing strategic development of the Attobody platform and advancement of the Company’s emerging pipeline candidates, Attovia has established Clinical and Scientific Advisory Boards comprised of biopharmaceutical industry veterans and academic experts.